Does Low-Dose Seretide Reverse Chronic Obstructive Pulmonary Disease and Are the Benefits Sustained Over Time? An Open-Label Swedish Crossover Cohort Study Between 1999 and 2005

Stefan RustscheffDepartment of Internal Medicine, Varnamo General Hospital, Varnamo, SwedenCorrespondence[email protected]

, M.D. &

Louise RydénDepartment of Internal Medicine, Varnamo General Hospital, Varnamo, Sweden

, M.D., M.Sc.

References

Hanania NA, Darken P, Horstman D, Reisner C, Lee B, Davis S, Shah T. The efficacy and safety of fluticasone propionate (250 μg)/salmeterol (50 μg) combined in the discus inhaler for the treatment of COPD. Chest 1003; 124:834–843.
Google Scholar
Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, Anderson J, Maden C, Trial of Inhaled Steroids and long-acting beta2 agonists study group. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: A randomised controlled trial. Lancet 2003; 361:449–456.
PubMed Web of Science ®Google Scholar
Cazzola, M, Di Lorenzo G, Di Rema F, Calderaro F, Testi R, Centanni S. Additive effects of salmeterol and flucticasone or theophylline in COPD. Chest 2000; 118:1576–1581.
PubMed Web of Science ®Google Scholar
Burrows B, Earl RH. Course and prognosis of chronic and obstructive lung disease. A prospective study of 200 patients. N Engl J Med 1969; 280:397.
PubMed Web of Science ®Google Scholar
Mitchell RS. Outlook in emphysema and chronic bronchitis. N Eng J Med 1969; 280:445.
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Does Low-Dose Seretide Reverse Chronic Obstructive Pulmonary Disease and Are the Benefits Sustained Over Time? An Open-Label Swedish Crossover Cohort Study Between 1999 and 2005

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Does Low-Dose Seretide Reverse Chronic Obstructive Pulmonary Disease and Are the Benefits Sustained Over Time? An Open-Label Swedish Crossover Cohort Study Between 1999 and 2005

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date